Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B study of ADX10059 in GERD patients partial responders to PPI
2008-005105-18Phase 2Completed
- Sponsor
- Addex Therapeutics Ltd
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of raseglurant in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Addex Therapeutics Ltd. Primary endpoint: Primary efficacy endpoint. Started Sep 2008; status: completed.
02
Drugs
raseglurant
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2008-005105-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005105-18.